StockData

Evommune vs HCW Biologics

EVMN and HCWB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How EVMN and HCWB compare

Evommune is the larger company, worth 179 times as much as HCW Biologics ($255M against $1.4M).

HCW Biologics grew revenue faster over the last twelve months (700% versus −100% for Evommune).

Evommune scores higher on the StockData Score (7 against 6 for HCW Biologics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricEVMNHCWB
Size and price
Market cap$255M$1.4M
Share price$7.02$0.777
Change, 1 year−61.6%−95.7%
Change, 5 years–−99.9%
Beta (5Y)0.942.48
Employees48–
StockData Score
Total score7 (better)6
Valuation score13 (better)
Growth score02 (better)
Performance score01 (better)
Health score6 (better)0
Dividend score00
Valuation
P/S–0.2×
P/B1.0×0.2× (better)
FCF yield−35.7%–
Fair value–$15.10
Margin of safety–94.9%
Growth
Revenue growth (TTM)−100%700% (better)
Revenue growth, 5Y average–−57.9%
Profitability
Gross margin–96.7%
Operating margin–−115%
Net margin–−83.8%
Return on equity−331%−151% (better)
Return on invested capital–−70.7%
Financial health
Debt / equity0.000.88 (better)
Interest coverage–−14.0×
Current ratio8.52 (better)0.06
Altman Z-score3.36 (better)−7.21
Piotroski F-score5 (better)2
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions95.4%5.6%
Held by insiders51.6%34.9%
Insider net buying, 12 months−$2.1M$532K (better)
Short interest, % of float19.3%4.1%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.